A farmer in Uttarakhand selling dried Ashwagandha roots to a Haridwar processing unit earns three times the income of a wheat farmer on the same plot. That income gap is the story of medicinal plants in India — a sector where the underlying demand is global, the supply chain is professionalising, and the government is funding the transition from wild collection to organised cultivation.
India is the world's largest producer and supplier of medicinal plants, with over 6,000 plant species documented for therapeutic use. Yet demand consistently outpaces supply for the 20–25 high-value species that anchor the global herbal products trade. For entrepreneurs willing to enter at the cultivation, processing, or value-addition stage, the structural supply gap is the opportunity.
|
At a Glance: Starting a Medicinal Plants Business in India
India Medicinal Plants Market (2023–24): INR 32,000 crore+ (National Medicinal Plants Board)
Global Herbal Medicine Market CAGR: ~7.5% through 2030 (Ministry of AYUSH estimates)
Minimum Investment (Cultivation, 5 acres): INR 3–8 lakh; (Processing Unit): INR 15–30 lakh
Key States: Uttarakhand, Himachal Pradesh, Madhya Pradesh, Rajasthan, Gujarat, Tamil Nadu
Key Licence Required: Medicinal Plants Cultivation Registration (state forest/agriculture dept.)
India Medicinal Herb Exports: USD 800 million+ (APEDA, FY2023)
|
The Case for Entering the Medicinal Plants Sector Now
India's medicinal plants and herbal products sector is at an inflection point, and the timing for new entrants has rarely been better. Post-COVID consumer behaviour shifted globally toward preventive and natural health solutions — a trend that has proved durable. The Ministry of AYUSH estimated that AYUSH product consumption in India rose by 40% in the two years following the pandemic, driven by demand for immunity-boosting herbs like Giloy, Tulsi, and Ashwagandha.
The export angle is equally compelling. India exports medicinal herbs and botanical extracts to over 60 countries. The global herbal medicine market was valued at USD 180 billion in 2023 and is growing at 7.5% annually (Ministry of AYUSH long-term assessment). Europe and North America are the largest markets, and both are tightening sourcing standards — which favours certified Indian suppliers over wild-collected competitors.
Government policy is a third reason to move now. The National Medicinal Plants Board (NMPB), operating under the Ministry of AYUSH, provides financial assistance for cultivation, post-harvest management, and market linkage. The scheme covers 140 priority species and supports cultivation at 50% cost subsidy for the first two years. No other agricultural input subsidy in India comes close to this level of direct financial support.
Import substitution offers a fourth driver. India imports significant quantities of Chinese herbal ingredients — notably Ginseng, Schisandra, and various TCM botanicals — for use in Ayurvedic and nutraceutical formulations. Domestic cultivation of substitute species creates both cost advantages and supply security for Indian manufacturers.
The processing and value-addition segment is where the highest margins reside. Raw dried herbs sell for INR 50–200 per kg. Standardised extracts of the same herb can sell for INR 2,000–15,000 per kg. An entrepreneur who moves up the value chain from cultivation to extraction and standardisation can multiply revenue per hectare five to fifteen times. This is the opportunity that large AYUSH companies like Dabur, Himalaya, and Hamdard understand — and that the MSME space is now beginning to access.
|
India cultivates medicinal plants on approximately 5.5 lakh hectares, but the National Medicinal Plants Board estimates that organised, certified cultivation covers only 30% of this area — meaning 70% of raw material is still wild-collected. This creates quality and supply-chain risk for buyers, and a premium opportunity for certified growers.
|
Demand Data, Market Trends, and High-Value Species
Domestic AYUSH industry consumption of medicinal herbs grew from INR 18,000 crore in FY2020 to INR 32,000 crore in FY2024 (NMPB annual data). The high-demand medicinal plants India — Ashwagandha, Senna, Isabgol, Tulsi, Brahmi, Neem, Aloe Vera, Stevia, and Kalmegh — collectively account for over 60% of commercial cultivation area.
|
Year
|
India AYUSH Herb Consumption (INR Crore)
|
Herb Exports (USD Million)
|
YoY Growth
|
|
FY2020
|
18,000
|
480
|
Baseline
|
|
FY2021
|
21,500
|
530
|
19.4%
|
|
FY2022
|
25,000
|
620
|
16.3%
|
|
FY2023
|
28,500
|
780
|
14.0%
|
|
FY2024
|
32,000
|
850
|
12.3%
|
|
FY2027 (Proj.)
|
48,000
|
1,300
|
CAGR ~14%
|
|
FY2030 (Proj.)
|
65,000
|
2,000
|
CAGR ~12%
|
|
FY2035 (Proj.)
|
90,000
|
3,500
|
CAGR ~8-10% (assumption)
|
Sources: National Medicinal Plants Board (Ministry of AYUSH), APEDA. Projections beyond FY2024 are CAGR-based estimates.
|
Ashwagandha (Withania somnifera) exports from India crossed USD 120 million in FY2023, making it the single largest medicinal herb export by value. APEDA data shows that the United States accounts for 40% of Ashwagandha extract imports from India — and demand continues to grow at 20%+ annually.
|
Government Data and Ministry Support for Medicinal Plant Entrepreneurs
The NMPB has committed INR 2,300 crore for the Centrally Sponsored Scheme on Medicinal Plants between 2021 and 2026. This is not aspirational — the funds are being disbursed. State implementation societies under the scheme have already onboarded 2.8 lakh farmers in 25 states as of FY2024.
The medicinal plants cultivation government scheme supports certified organic cultivation, post-harvest infrastructure (drying sheds, cold storage), market linkages with AYUSH companies, and geo-tagging of cultivation plots. Certified growers receive a 20–30% price premium from major buyers who need traceable, quality-assured supply.
|
Indicator
|
Value
|
Source & Year
|
|
NMPB Scheme Allocation (2021–26)
|
INR 2,300 crore
|
Ministry of AYUSH, 2021
|
|
Farmers Onboarded Under NMPB Scheme
|
2.8 lakh
|
NMPB, FY2024
|
|
Priority Species Supported
|
140 species
|
NMPB, 2024
|
|
States Covered Under NMPB Scheme
|
25 states + UTs
|
Ministry of AYUSH, 2024
|
|
Certified Organic Medicinal Herb Growers
|
45,000+
|
APEDA, 2023
|
|
AYUSH Industry Turnover
|
INR 1.2 lakh crore
|
Ministry of AYUSH, 2023
|
|
Medicinal Plant Gene Bank Accessions
|
35,000+ species
|
CIMAP / CSIR, 2023
|
|
India Share in Global Botanical Exports
|
~12%
|
DGFT / APEDA, 2023
|
Sources: National Medicinal Plants Board, Ministry of AYUSH, APEDA, DGFT.
Government Schemes for Medicinal Plant Entrepreneurs
The NMPB's centrally sponsored scheme provides 50% cost subsidy for cultivation of 140 identified priority species. The subsidy is released in two tranches: 75% at planting and 25% post verification of stand. An entrepreneur cultivating five acres of Ashwagandha can receive direct subsidy of INR 1–2 lakh depending on the state implementation norms.
The National AYUSH Mission (NAM) co-funds quality certification, good agricultural practices (GAP) training, and primary processing infrastructure. PMFME (PM Formalisation of Micro Food Enterprises) scheme also covers herbal product processing units with 35% capital subsidy up to INR 10 lakh.
APEDA (Agricultural and Processed Food Products Export Development Authority) offers market development assistance for organic medicinal herb exporters — including participation in international trade fairs, quality testing cost reimbursement, and buyer-connect missions. First-time exporters can access these facilities at minimal cost.
Export Opportunity: India's Medicinal Herb Trade on the Global Stage
India exports medicinal herbs, botanicals, and standardised extracts to over 60 countries. The United States, Germany, Japan, UAE, and the United Kingdom are the top five destination markets. Ashwagandha, Senna, Isabgol husk, Neem, and Tulsi extracts account for the bulk of exports by value (APEDA, FY2023).
The import side is equally revealing. India spends approximately INR 4,000–5,000 crore on herbal raw material imports — primarily from China — creating an import substitution case for domestic producers of species like Ginseng-substitute herbs, Coptis, and Schisandra.
The EU's tightened botanical sourcing regulations (EU Traditional Herbal Products Directive) and US FDA guidelines on dietary supplement sourcing have created a premium for traceable, GAP-certified Indian herbs. Certified Indian suppliers command 15–25% price premiums over uncertified sources in these markets.
Major Players in the Indian Medicinal Plants and Herbal Sector
|
Company / Organisation
|
Segment & Note
|
|
Dabur India Ltd.
|
Largest AYUSH company; major buyer of Ashwagandha, Brahmi, Amla
|
|
Himalaya Drug Company
|
Vertically integrated; own cultivation farms + processing
|
|
Patanjali Ayurved
|
High-volume consumer herbal products; major domestic buyer
|
|
Arjuna Natural Ltd.
|
Standardised extract manufacturer; significant exporter
|
|
Aimil Pharmaceuticals
|
MSME-scale Ayurvedic formulations; domestic market focus
|
|
Synthite Industries
|
Botanical and spice extract exporter; Tamil Nadu-based
|
|
Kesar Organics
|
Organic certified herb exporter; Gujarat-based MSME
|
|
CSIR-CIMAP
|
Govt. R&D; provides planting material and GAP support to growers
|
Market Outlook Through 2035
India's medicinal plants and botanical extracts market is projected to grow from INR 32,000 crore in FY2024 to INR 90,000 crore by FY2035 at an assumed CAGR of 9–10%. This growth is driven by four secular trends: rising domestic AYUSH consumption, expanding nutraceuticals industry, growing global demand for natural health products, and policy-driven shift from wild collection to organised cultivation.
A business started in this sector today — whether at cultivation, primary processing, extract manufacturing, or branded finished goods — positions itself in a market that will be three times larger within a decade. The first five years will see the most competitive advantage, as organised supply chains are still forming and buyer relationships are not yet locked in.
|
Consultant's Perspective
Do not enter medicinal plant cultivation without buyer linkage. The price spread between a cultivator who sells in the open market and one with a direct offtake agreement with an AYUSH company or extract manufacturer is 30–50%. NMPB's market linkage programme can facilitate introductions. Organic certification from APEDA adds a further 20–25% premium but requires three years of chemical-free cultivation documentation — start that documentation from year one even before applying.
|
Q&A: What Founders Ask Before Entering This Sector
Q: Which medicinal plant is most profitable to cultivate in India right now?
A: Ashwagandha, Senna, and Stevia consistently rank at the top for profitability per acre in dry and semi-arid regions. Brahmi and Giloy are high-value in humid climates. NMPB publishes an updated priority species list annually with state-specific growing suitability — consult it before choosing a crop.
Q: What is the minimum land holding needed to make medicinal plant cultivation commercially viable?
A: Five acres is the practical minimum for standalone cultivation. Below that, agglomeration with a Farmer Producer Organisation (FPO) is strongly recommended. NABARD and NMPB actively support FPO formation in this sector, and buyers prefer dealing with aggregated volumes above five metric tonnes per season.
Q: How do I get a direct buyer for my harvest?
A: NMPB's market linkage programme connects certified growers to registered AYUSH companies. Additionally, APEDA registers herbal exporters and facilitates buyer-seller meets in target countries. Some states — Uttarakhand, MP — have medicinal plants procurement boards that act as aggregators.
Q: Is organic certification mandatory for export?
A: It is not legally mandatory but practically necessary for European and US markets, where certified organic commands 20–30% premium. APEDA handles organic certification for export. The certification process takes 36 months; plan accordingly.
Q: What government subsidy is available for setting up a herb drying and processing unit?
A: NMPB provides cost subsidy for primary processing infrastructure. The PMFME scheme provides 35% capital subsidy up to INR 10 lakh for micro food processing enterprises including herbal product units. Some state MSME departments offer additional assistance.
Q: Can I start a medicinal plant business on leased agricultural land?
A: Yes, in most states. However, forest land and tribal land have restrictions on commercial cultivation of certain species. Verify with the state forest department and revenue department for the specific species and location before signing any lease.
Q: Which districts in India are best for Ashwagandha cultivation?
A: Mandsaur and Neemuch in Madhya Pradesh, Nagaur and Tonk in Rajasthan, and parts of Gujarat's Saurashtra region are recognised as the premier Ashwagandha belts. These districts have established trader networks, testing labs, and NMPB implementation infrastructure.
Q: What quality standards do buyers of medicinal herbs require?
A: Domestic AYUSH manufacturers follow WHO monographs and Ayurvedic Pharmacopoeia of India standards. Exporters targeting the EU need a certificate of analysis from an accredited lab, and organic exporters need NPOP or NOP certification. Heavy metal and pesticide residue limits are strictly enforced by importing countries.
Q: How does the NMPB subsidy actually reach me as a farmer?
A: Through the state AYUSH department and implementing society (usually the State Medicinal Plants Board). Register with your state board, submit a cultivation plan for an approved species, receive a field verification visit, then claim the first tranche. The process takes 45–90 days from application to first disbursement.
Q: Is value-added processing of herbs more profitable than cultivation alone?
A: Significantly more. A dried Ashwagandha root fetches INR 80–120 per kg. Standardised Ashwagandha extract (2.5% withanolides) sells for INR 800–1,500 per kg to domestic formulators and INR 2,000–3,000 per kg to export buyers. A modestly scaled extraction unit processing 500 kg per month can generate INR 12–20 lakh monthly revenue from the same raw material.
The Bottom Line
Medicinal plant cultivation and processing is one of India's most under-exploited agricultural business opportunities. Demand is structural, government support is among the most generous in any agri-sub-sector, and the global market is actively seeking certified Indian suppliers. The combination of a 50% cultivation subsidy, APEDA export facilitation, and CGTMSE lending for processing units makes the capital commitment manageable even for first-generation entrepreneurs.
The single most important first step is to register with your State Medicinal Plants Board, identify the two or three priority species most suitable for your agro-climatic zone, and initiate buyer conversations before planting. NMPB's market linkage programme is the starting point. Enter with a processing plan, not just a cultivation plan — that is where the real returns are.
References
1. National Medicinal Plants Board (NMPB), Ministry of AYUSH — Centrally Sponsored Scheme data; Priority Species List; farmer registration data, FY2024.
2. Ministry of AYUSH — National AYUSH Mission progress reports; AYUSH industry turnover estimates, 2023.
3. APEDA (Agricultural and Processed Food Products Export Development Authority) — Medicinal herb and botanical export statistics, FY2023.
4. DGFT (Directorate General of Foreign Trade) — Medicinal herbs trade data and HS code-wise export statistics, 2023.
5. CSIR-CIMAP (Central Institute of Medicinal and Aromatic Plants) — Research and cultivation support programmes, 2023.
6. NABARD — Farmer Producer Organisation (FPO) support and medicinal plants agri-financing guidelines, 2023.
